Disc Medicine, Inc. (NASDAQ:IRON) Shares Acquired by Strs Ohio

Strs Ohio increased its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 66.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,000 shares of the company’s stock after acquiring an additional 400 shares during the quarter. Strs Ohio’s holdings in Disc Medicine were worth $57,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the stock. China Universal Asset Management Co. Ltd. purchased a new position in shares of Disc Medicine during the fourth quarter valued at $161,000. Bleakley Financial Group LLC purchased a new position in shares of Disc Medicine during the fourth quarter valued at $215,000. Simplicity Solutions LLC purchased a new position in shares of Disc Medicine during the fourth quarter valued at $215,000. Legato Capital Management LLC purchased a new position in shares of Disc Medicine during the fourth quarter valued at $305,000. Finally, SG Americas Securities LLC purchased a new position in shares of Disc Medicine during the fourth quarter valued at $528,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Disc Medicine

In other news, Director William Richard White sold 2,560 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The stock was sold at an average price of $31.80, for a total value of $81,408.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 4.71% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on IRON shares. BMO Capital Markets lowered their price target on Disc Medicine from $80.00 to $50.00 and set an “outperform” rating on the stock in a report on Tuesday, April 2nd. Morgan Stanley lowered their price target on Disc Medicine from $75.00 to $40.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 2nd. Wedbush reissued an “outperform” rating and set a $43.00 price objective (down previously from $84.00) on shares of Disc Medicine in a research report on Monday, April 1st. Stifel Nicolaus lifted their price objective on Disc Medicine from $71.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, April 8th. Finally, Raymond James reissued an “outperform” rating and set a $40.00 price objective (down previously from $75.00) on shares of Disc Medicine in a research report on Monday, April 1st. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Disc Medicine presently has an average rating of “Moderate Buy” and a consensus target price of $57.29.

Disc Medicine Price Performance

Shares of NASDAQ:IRON opened at $28.53 on Thursday. Disc Medicine, Inc. has a fifty-two week low of $25.60 and a fifty-two week high of $77.60. The stock has a market capitalization of $688.71 million, a P/E ratio of -8.17 and a beta of 0.18. The business has a 50-day moving average of $49.47 and a two-hundred day moving average of $54.46.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.22). As a group, research analysts expect that Disc Medicine, Inc. will post -4.44 EPS for the current fiscal year.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.